Cipla Patalganga facility gets EIR from USFDA
"Following the inspection by the United States Food and Drug Administration (USFDA) at the Patalganga manufacturing facility of the company from November 4, 2019, to November 13, 2019, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection," the homegrown pharma major said in a filing to the BSE.
New Delhi: Cipla on Monday announced the closure of inspection by the US health regulator at its Patalganga manufacturing facility in Maharashtra.
Also Read: No Relief: DOP Rejects Review Petition By CIPLA Challenging NPPA Price Fixation
"Following the inspection by the United States Food and Drug Administration (USFDA) at the Patalganga manufacturing facility of the company from November 4, 2019, to November 13, 2019, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection," the homegrown pharma major said in a filing to the BSE.
Headquartered in Mumbai, Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions. The company sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products, including Escitalopram (anti-depressant), Lamivudine and Fluticasone propionate. They are the world's largest manufacturer of antiretroviral drugs.
Also Read: SETBACK: Delhi HC Restricts Cipla From Launching Generic Version Of Apixaban
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd